Medical Device

The development and authorization of a COVID-19 vaccine is a critical scientific milestone in our efforts to combat this pandemic. Abbott  released findings today from a survey conducted by The Harris Poll, showing that Americans see testing as an essential partner to these new vaccines. Among the key findings: Importance of Testing as Partner to Vaccine: 82% of Americans say the COVID-19 vaccine rollout will be ...

- The development and authorization of a COVID-19 vaccine is a critical scientific milestone in our efforts to combat this pandemic. Abbott (NYSE: ABT) released findings today from a survey conducted by The Harris Poll, showing that Americans see testing as an essential partner to these new vaccines. Among the key findings:

  • Importance of Testing as Partner to Vaccine: 82% of Americans say the
    COVID-19 vaccine rollout will be more effective if it works in partnership with testing.
  • Precautionary Measures Support Vaccines: When asked whether a vaccine by itself or a layered strategy would help combat the pandemic and allow us to get back to normal as quickly as possible, 73% of Americans believe a COVID-19 vaccine cannot succeed without other precautionary measures . However, when asked about concerns following approval of a vaccine, many are concerned (very or somewhat) that testing (71%), mask wearing (75%), and social distancing (76%) will decline following vaccine authorization.

"Like the rest of the globe, Americans are anxious to return to normalcy. The authorization of vaccines is an important and tremendous development in our fight against COVID-19," said Andrea Wainer, executive vice president, Rapid and Molecular Diagnostics, Abbott. "Americans agree that we should stay vigilant in other important safety measures, including testing, mask wearing and social distancing. Abbott will remain focused on providing as many tests as possible so people can access them throughout the duration of the pandemic and beyond."

Since the onset of the pandemic, Abbott has launched eight COVID-19 tests for emergency use in the U.S. including lab-based and rapid molecular tests, antibody tests, and a rapid antigen test, which was recently authorized for at-home use with a prescription and certified virtual guide. Abbott has delivered more than 300 million COVID-19 tests worldwide.

As we await widespread access to the vaccine, Americans agree that testing remains essential to curbing the pandemic right now.

  • Role of Testing in Interim: 86% of Americans say testing will play a significant (very or somewhat) role in combatting the pandemic while we wait for vaccines to be made widely available.
  • Importance of Detecting Infectiousness: 66% of Americans say rapid antigen COVID-19 testing is a critical tool to combat the pandemic because of its ability to detect the most infectious people.

As initial doses of the vaccines are prioritized for populations like frontline healthcare workers and seniors in long-term care facilities, rapid antigen tests are as important as ever to identify infectious individuals and slow the spread of the virus among those who have not been vaccinated.

"With cases rising and critical winter months ahead, we must continue to use every preventative measure available to us to slow the spread of the virus," said Mary Rodgers , PhD., principal scientist, Diagnostics, Abbott. "It's important that diagnostic companies, public health leaders, policymakers and citizens continue to advocate for the role of vaccines and testing in partnership with other important safety measures like mask wearing, social distancing and hand washing."

This survey was conducted online within the United States by The Harris Poll on behalf of Abbott from December 10 December 14, 2020 , among 2,064 U.S. adults ages 18 and older.

For a summary of the data, please click here .

About Abbott
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 107,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com , on LinkedIn at www.linkedin.com/company/abbott-/ , on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews.

Cision View original content: http://www.prnewswire.com/news-releases/as-vaccines-roll-out-americans-see-covid-19-testing-as-important-partner-301197237.html

SOURCE Abbott

News Provided by PR Newswire via QuoteMedia

Johnson & Johnson to Participate in Citi's 2022 Virtual Healthcare Conference

- Johnson & Johnson (NYSE: JNJ) will participate in Citi's 2022 Virtual Healthcare Conference on Wednesday, February 23 rd Ashley McEvoy Executive Vice President, Worldwide Chairman, Medical Devices will represent the Company in a session scheduled at 11:00 a.m. (Eastern Time) .

This conference call will be available to investors and other interested parties by visit the Johnson & Johnson website at www.investor.jnj.com .

Keep reading... Show less

Thermo Fisher Scientific Earns Top Score for LGBTQ+ Workplace Equality for Seventh Consecutive Year

Thermo Fisher Scientific Inc., (NYSE:TMO), the world leader in serving science, received a score of 100 on the Human Rights Campaign Foundation's 2022 Corporate Equality Index (CEI) for the seventh consecutive year. As the national benchmarking tool measuring policies, practices and benefits pertinent to lesbian, gay, bisexual, transgender and queer (LGBTQ) employees, the CEI is a driving force for LGBTQ+ workplace inclusion.

Keep reading... Show less

Bausch Health Announces Launch Of Private Offering Of Senior Secured Notes

Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health" or the "Company") announced today that it has launched an offering of $1.0 billion aggregate principal amount of new senior secured notes due 2027 (the "Notes"). As previously announced, the Company is also seeking to refinance its existing credit agreement (the "Credit Agreement" and such refinancing, the "Credit Agreement Refinancing"). The refinanced Credit Agreement is expected to consist of approximately $2.5 billion of term B loans (the "New Term B Loans") and a $975 million revolving credit facility. The Credit Agreement Refinancing is expected to occur upon completion of the initial public offering ("IPO") of Bausch + Lomb Corporation ("Bausch + Lomb" and such offering, the "Bausch + Lomb IPO") and a related debt financing by Bausch + Lomb (the "Bausch + Lomb Debt Financing").

The proceeds from the offering of the Notes, along with the expected proceeds from the New Term B Loans, the Bausch + Lomb IPO and the repayment of an intercompany note owed to us by Bausch + Lomb (which repayment is expected to be funded by the Bausch + Lomb Debt Financing), are expected to be used to fund the Company's previously announced conditional redemption in full of its outstanding 6.125% Senior Notes due 2025 (the "6.125% Notes due 2025"), refinance all of the existing Term B Loans, fund the Company's previously announced conditional partial redemption of its outstanding 9.000% Senior Notes due 2025 (the "9.000% Notes due 2025 and, collectively with the 6.125% Senior Notes due 2025, the "Existing Notes") and to pay related fees, premiums and expenses.

Keep reading... Show less

Danaher Reports Fourth Quarter And Full Year 2021 Results

- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2021. All results in this release reflect only continuing operations unless otherwise noted.

For the quarter ended December 31, 2021 , net earnings were $1.8 billion , or $2.39 per diluted common share which represents a 44.0% year-over-year increase from the comparable 2020 period.

Keep reading... Show less

Abbott Reports Strong Fourth-Quarter 2021 Results; Issues 2022 Forecast

Abbott (NYSE: ABT) today announced financial results for the fourth quarter and full year ended Dec. 31, 2021 and issued its financial outlook for 2022.

  • Fourth-quarter sales of $11.5 billion increased 7.2 percent on a reported basis and 7.7 percent on an organic basis, which excludes the impact of foreign exchange.
  • Fourth-quarter GAAP diluted EPS was $1.11 and adjusted diluted EPS, which excludes specified items, was $1.32 .
  • Full-year 2021 GAAP diluted EPS from continuing operations was $3.94 and adjusted diluted EPS from continuing operations was $5.21 , reflecting 42.7% growth versus the prior year. 1
  • Global COVID-19 testing-related sales were $2.3 billion in the fourth quarter and $7.7 billion for the full-year. Abbott has distributed more than 1.4 billion COVID-19 tests since the start of the pandemic.
  • Abbott issues full-year 2022 guidance for diluted EPS from continuing operations on a GAAP basis of at least $3.43 and full-year adjusted diluted EPS from continuing operations of at least $4.70 .
  • Full-year 2022 guidance includes an initial COVID-19 testing-related sales forecast of $2.5 billion , which Abbott expects to occur early in the year and will update on a quarterly basis.
  • Abbott's R&D pipeline continues to deliver a steady cadence of new products. Select 2021 highlights include U.S. Centers for Medicare & Medicaid Services expanded reimbursement for MitraClip ® , U.S. launches of Amplatzer ® Amulet ® , NeuroSphere Virtual Clinic, and Portico ® transcatheter aortic valve replacement (TAVR) system, along with the international launch of Navitor TAVR system.

"2021 was an outstanding year for Abbott," said Robert B. Ford , chairman and chief executive officer, Abbott. "We achieved more than 40 percent EPS growth, exceeding the baseline EPS guidance we set at the beginning of last year and, importantly, continued to advance our new product pipeline across the portfolio."

Keep reading... Show less
Avricore Health CEO and Special Guests Join Radius Research for Investor Update

Avricore Health CEO and Special Guests Join Radius Research for Investor Update

Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") is excited to be joined by Shoppers Drug Mart Pharmacist and Associate Owner, Mohamad Adel Elsabakhawi and Abbott Rapid Diagnostics' General Manager Daniel St. Pierre and National Sales Manager, Soul Khan.

"The Company enjoyed an incredible year in 2021, and throughout the Holidays and the beginning of the New Year, we have continued to finalize key agreements which will lead to substantial growth this year." said Avricore Health CEO, Hector Bremner. "Our partners are as excited as we are and we look forward to deepening our collaboration."

Keep reading... Show less

Latest Press Releases

Related News

×